Trial · NCT01651806

Weighted Versus Uniform Dose of Tranexamic Acid in Patients Undergoing Primary, Knee Arthroplasty

NCT01651806, Phase 2, Phase 3, Completed, Rush University Medical Center; results first posted 2017-12-13

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Weighted Versus Uniform Dose of Tranexamic Acid in Patients Undergoing Primary, Knee Arthroplasty. Trials, record NCT01651806. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01651806

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Weighted Versus Uniform Dose of Tranexamic Acid in Patients Undergoing Primary, Knee Arthroplasty
NCT number: NCT01651806
Status: Completed
Phases: Phase 2, Phase 3
Enrollment: 65 participants, actual
Lead sponsor: Rush University Medical Center
Conditions: Osteoarthritis, Intraoperative Bleeding
Interventions: Tranexamic Acid standard dose, Females Tranexamic Acid weighted dose, Females receiving a uniform dose of TA, Males Weighted Dose TA
First posted: 2012-07-27
Last updated: 2017-12-13
Results first posted: 2017-12-13

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Primary Intra-operative Blood Loss	Intra-operative, an average of 3 hours	Record intra-operative blood loss through drain output
Primary	Document Incidences of DVT and Other Thromboembolic Events.	1 year	DVT = Deep Venous thrombosis Patients were assessed every 12 hours for development of pain within the lower extremity. Any reported muscle pain was evaluate with a bedside venous ultrasound by an ultrasound technician.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Primary Intra-operative Blood Loss	Intra-operative, an average of 3 hours		mL	MEAN
PRIMARY	Document Incidences of DVT and Other Thromboembolic Events.	1 year		Events	NUMBER

Source ClinicalTrials.gov

Results by group10

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Primary Intra-operative Blood Loss	Female Uniform Single Dose TA Patient	100.00	Standard Deviation 31.69	mL
Primary Intra-operative Blood Loss	Female Weighted Dose TA Patient	65.00	Standard Deviation 8.50	mL
Primary Intra-operative Blood Loss	Control	142.80	Standard Deviation 197	mL
Primary Intra-operative Blood Loss	Male Uniform Single Dose TA	100.00	Standard Deviation 31.69	mL
Primary Intra-operative Blood Loss	Male Weighted Dose TA Patient	65.00	Standard Deviation 8.50	mL
Document Incidences of DVT and Other Thromboembolic Events.	Female Uniform Single Dose TA Patient	1		Events
Document Incidences of DVT and Other Thromboembolic Events.	Female Weighted Dose TA Patient	1		Events
Document Incidences of DVT and Other Thromboembolic Events.	Control	0		Events
Document Incidences of DVT and Other Thromboembolic Events.	Male Uniform Single Dose TA	0		Events
Document Incidences of DVT and Other Thromboembolic Events.	Male Weighted Dose TA	0		Events

Source ClinicalTrials.gov

Participant flow15

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Female Uniform Single Dose TA Patient	13
Overall Study	STARTED	Female Weighted Dose TA Patient	12
Overall Study	STARTED	Control	25
Overall Study	STARTED	Male Uniform Single Dose TA Patient	7
Overall Study	STARTED	Male Weighted Dose TA Patient	8
Overall Study	COMPLETED	Female Uniform Single Dose TA Patient	13
Overall Study	COMPLETED	Female Weighted Dose TA Patient	12
Overall Study	COMPLETED	Control	25
Overall Study	COMPLETED	Male Uniform Single Dose TA Patient	7
Overall Study	COMPLETED	Male Weighted Dose TA Patient	8

1 to 10 of 15Source ClinicalTrials.gov

See all 15 participant flow

Adverse events15

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Blood Transfusion	Blood and lymphatic system disorders	Female Uniform Single Dose TA Patient	0	13	0
other	Blood Transfusion	Blood and lymphatic system disorders	Female Weighted Dose TA Patient	1	12	1
other	Blood Transfusion	Blood and lymphatic system disorders	Control	10	25	10
other	Blood Transfusion	Blood and lymphatic system disorders	Male Uniform Single Dose TA Patient	0	7	0
other	Blood Transfusion	Blood and lymphatic system disorders	Male Weighted Dose TA	0	8	0
serious	Symptomatic DVT	Blood and lymphatic system disorders	Female Uniform Single Dose TA Patient	0	13	0
serious	Symptomatic DVT	Blood and lymphatic system disorders	Female Weighted Dose TA Patient	1	12	1
serious	Symptomatic DVT	Blood and lymphatic system disorders	Control	0	25	0
serious	Symptomatic DVT	Blood and lymphatic system disorders	Male Uniform Single Dose TA Patient	0	7	0
serious	Symptomatic DVT	Blood and lymphatic system disorders	Male Weighted Dose TA	0	8	0

1 to 10 of 15Source ClinicalTrials.gov

See all 15 adverse events

Adverse event totals15

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Female Uniform Single Dose TA Patient
Total, all-cause mortality	Female Weighted Dose TA Patient
Total, all-cause mortality	Control
Total, all-cause mortality	Male Uniform Single Dose TA Patient
Total, all-cause mortality	Male Weighted Dose TA
Total, other adverse events	Female Uniform Single Dose TA Patient	0	13
Total, other adverse events	Female Weighted Dose TA Patient	1	12
Total, other adverse events	Control	10	25
Total, other adverse events	Male Uniform Single Dose TA Patient	0	7
Total, other adverse events	Male Weighted Dose TA	0	8

1 to 10 of 15Source ClinicalTrials.gov

See all 15 adverse event totals

Papers3

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
14763696	BACKGROUND	PubMed
19007970	BACKGROUND	PubMed
20063079	BACKGROUND	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01651806

GET https://conductscience.org/api/trials/v1/NCT01651806/registered

API reference For AI assistants